Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

Davies, F, Rifkin, R, Costello, C et al. (24 more authors) (2021) Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Annals of Hematology, 100 (9). pp. 2325-2337. ISSN 0939-5555

Abstract

Metadata

Item Type: Article
Authors/Creators:
  • Davies, F
  • Rifkin, R
  • Costello, C
  • Morgan, G
  • Usmani, S
  • Abonour, R
  • Palumbo, A
  • Romanus, D
  • Hajek, R
  • Terpos, E
  • Cherepanov, D
  • Stull, DM
  • Huang, H
  • Leleu, X
  • Berdeja, J
  • Lee, HC
  • Weisel, K
  • Thompson, M
  • Boccadoro, M
  • Zonder, J
  • Cook, G ORCID logo https://orcid.org/0000-0001-7196-7364
  • Puig, N
  • Vela-Ojeda, J
  • Farrelly, E
  • Raju, A
  • Blazer, M
  • Chari, A
Copyright, Publisher and Additional Information:

© The Author(s) 2021 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Keywords: Relapsed refractory multiple myeloma; Proteasome inhibitor triplet therapy; Real-world; Bortezomib; Carfilzomib; Ixazomib; Daratumumab; Lenalidomide; Pomalidomide
Dates:
  • Published: September 2021
  • Published (online): 10 May 2021
  • Accepted: 22 March 2021
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 24 May 2021 13:49
Last Modified: 25 Jun 2023 22:39
Status: Published
Publisher: Springer
Identification Number: 10.1007/s00277-021-04534-8
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics